Overview

Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline

Status:
Recruiting

Trial end date:
2026-01-31

Target enrollment:

Participant gender:

Summary

This is a prospective, phase 3 randomized controlled clinical trial. Cervical cancer patients who undergo radical surgery but do not meet criteria of adjuvant therapy according to NCCN guideline are enrolled to receive adjuvant chemotherapy. The primary endpoint was disease-free survival (DFS) rate at 3 year. The secondary endpoints were 5-year DFS, overall survival (OS) and safety.

Phase:

Phase 3

Details

Lead Sponsor:

Huazhong University of Science and Technology

Collaborators:

First Affiliated Hospital of Chongqing Medical University
Hunan Cancer Hospital
Obstetrics & Gynecology Hospital of Fudan University
Qilu Hospital of Shandong University
The Third Xiangya Hospital of Central South University
Women's Hospital School Of Medicine Zhejiang University

Treatments:

Carboplatin
Docetaxel
Paclitaxel